Purpose: The aim of this study was to examine the impact of detoxification from prescription opioids on the quality of life (QoL) and pain levels among patients reliant on these medications for chronic pain management. Objective: Long-term use of opioids for pain management may lead to a range of adverse effects, including tolerance, dependence, significant societal costs, and a decline in overall quality of life (QoL). Despite these challenges, there is a limited amount of research focusing on the effects of detoxification and its impact on the QoL for patients with chronic pain tolerant to prescription opioids. Methods: This prospective study included 45 patients who underwent elective detoxification from prescription opioids. Prescription opioids were discontinued during the detoxification treatment in 44 of the 45 cases. QoL was monitored using SF-36v2™ questionnaires administered before detoxification, on the day of discharge, and at least six months after detoxification. Pain levels were assessed using Visual Analogue Scale (VAS) scores before and after the detoxification process. Results: The study was fully completed by 30 patients. At the third SF-36v2™ evaluation, 25 out of 30 patients (83.3%) reported the detoxification treatment as beneficial to their overall health status compared to that before the treatment, and SF-36v2™ questionnaires after detoxification were significantly higher than before the treatment (p < 0.001). A decreased pain level right after the detoxification was reported by 44 of the 45 patients (97.7%), with a significant average reduction of 4.51 points observed (p < 0.001). Conclusions: The observed enhancement in QoL, significant reduction in pain, and cessation of opioid use in most patients with chronic pain tolerant to prescription opioids following opioid detoxification indicate that this method of treatment can be safely and effectively administered and must be considered for chronic pain patients.
Objectives: To investigate the correlation between baseline serum concentrations of 25-hydroxyvitamin D (25-OHD) and quality of life (QoL), as well as pain perception in patients with chronic pain with long-term prescription opioid usage before opioid detoxification. Methods: We prospectively studied 45 patients with chronic pain with long-term prescription opioid usage who were selected for elective detoxification. Baseline serum 25-OHD levels were measured prior to detoxification, classifying patients as either vitamin D deficient (<75 nmol/L) or sufficient (≥75 nmol/L). QoL was assessed using the SF-36v2TM questionnaire, while pain levels were assessed using Visual Analogue Scale (VAS) scores before treatment. Results: Mean pain scores before detoxification of the patients with sufficient baseline 25-OHD levels vs. those with deficient levels were, respectively, 6.06 ± 2.32 vs. 6.86 ± 2.10 (normalized scores 1.22 ± 0.571 vs. 0.950 ± 0.632; p = 0.164). The analysis of SF-36v2™ questionnaire scores revealed minimal variation between groups (35.00 ± 14.198 vs. 34.97 ± 13.52), indicating no significant association between Vitamin D levels and QoL (p = 0.913). Conclusions: The analysis of baseline 25-OHD levels in relation to QoL assessments and pain scores did not reveal a statistically significant association, indicating that variations in baseline vitamin D levels may not substantially impact QoL or pain perception. Further studies may help determine how to assess and optimize vitamin D levels in patients with chronic pain on long-term prescription opioids.
Background: Procalcitonin (PCT) is widely used as a biomarker of bacterial infection, but it may also increase in non-infectious inflammatory states. This study investigated the association of PCT with muscle injury severity and renal dysfunction in patients with non-traumatic rhabdomyolysis. Methods: We prospectively enrolled 39 adults with non-traumatic rhabdomyolysis (n = 39). Admission and longitudinal laboratory data included creatine kinase (CK), myoglobin, PCT, C-reactive protein (CRP), creatinine, and urea. Associations were assessed using Spearman correlation analysis with false-discovery-rate correction for multiple comparisons. Independent predictors of admission PCT were evaluated using linear regression with PCT (log10) as the dependent variable. Longitudinal dynamics were analyzed using linear mixed-effects models and a generalized mixed-effects sensitivity model. Results: At admission, after false-discovery-rate correction, PCT remained positively correlated with creatinine, CK, urea, and CRP; the weaker correlation with myoglobin did not remain significant after correction. In the primary admission model, both creatinine (log10) and CK (log10) were independently associated with PCT (log10), whereas infection status was not. In the broader sensitivity model, only creatinine (log10) remained significant. Longitudinal analyses showed that CK (log10) remained independently associated with PCT over time, including in the gamma mixed-effects sensitivity model; in that model, infection status was not independently associated with PCT. Conclusions: In this exploratory single-centre cohort of patients with predominantly intoxication- or immobilization-related “found-down” non-traumatic rhabdomyolysis, PCT elevation was associated with markers of muscle injury and renal dysfunction. Infection status was not independently associated with PCT in the fitted models; however, the modest sample size means that smaller infection-related effects cannot be excluded. These findings should therefore be interpreted cautiously and require confirmation in larger, more etiologically diverse rhabdomyolysis cohorts.